Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neoadjuvant chemotherapy + SPIONs + SMF
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral, Intravenous
01
Overview
neoadjuvant chemotherapy + SPIONs + SMF is an experimental combination therapy being investigated for the treatment of osteosarcoma. This regimen combines standard-of-care neoadjuvant chemotherapy (typically the MAP regimen consisting of methotrexate, doxorubicin, and cisplatin) with the intratumoral injection of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) and the application of a Spinning Magnetic Field (SMF). The SPIONs are iron oxide-based nanoparticles that are activated by the SMF to enhance cancer cell death, potentially through mechanical disruption or localized hyperthermia. This approach is designed to increase tumor shrinkage and improve the feasibility of limb-salvage surgery for patients with various forms of osteosarcoma, including metastatic, localized, and high-grade cases. The therapy is currently being evaluated in a Phase 1 clinical trial led by the Second Affiliated Hospital, School of Medicine, Zhejiang University.
- Other names
- neoadjuvant chemotherapy+SPIONs/SMFSPIONs/SMF with Neoadjuvant Chemotherapy
02
Targets
DNATOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on neoadjuvant chemotherapy + SPIONs + SMF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neoadjuvant chemotherapy + SPIONs + SMF.